Publications by authors named "D A Foss"
Detection of PCV2d in Vaccinated Pigs in Colombia and Prediction of Vaccine T Cell Epitope Coverage against Circulating Strains Using EpiCC Analysis.
Vaccines (Basel)
September 2024
Article Synopsis
- Porcine circovirus type 2 (PCV2) is associated with porcine-circovirus-associated diseases (PCVADs), and while vaccination helps control these diseases, it does not provide complete immunity and may lead to vaccine failure.
- A study conducted in Colombia found that 82% of pigs and 92.9% of herds were infected with PCV2, with the PCV2d variant being the most prevalent.
- Histopathological examinations revealed common lung issues, and the study suggested that bivalent vaccines offer better immune coverage compared to monovalent vaccines despite ongoing clinical cases of PCV2.
Article Synopsis
- Scientists found a better way to change genes in human immune cells by using a special peptide that helps deliver CRISPR tools.
- This new method is easier, cheaper, and less harmful compared to older methods like electroporation.
- It allows for more successful gene editing and can help create improved T cells that fight tumors in mice.
Lokivetmab (Cytopoint®, Zoetis) is a canine monoclonal antibody that specifically binds and neutralizes interleukin (IL)-31. Lokivetmab is approved for use in dogs for the treatment of atopic dermatitis (AD) and allergic dermatitis. The laboratory safety of lokivetmab was evaluated in 2 studies by adapting the science-based, case-by-case approach used for preclinical and early clinical safety evaluation of human biopharmaceuticals.
View Article and Find Full Text PDFRecent publications suggest PCV2 vaccine-induced protection is superior when the vaccine and challenge are closely matched. PCV2's evolutionary rate, propensity for recombination, and genotype shifting, all provide rationale for modernizing PCV2 vaccines. One mechanism to increase a vaccine's epitope breadth is by designing a bivalent vaccine.
View Article and Find Full Text PDFPorcine Circovirus type 2 (PCV2) associated disease is one of the most economically important swine diseases worldwide. Vaccines reduce PCV2 disease by inducing humoral immunity (neutralizing antibodies) and cell-mediated immunity (CMI) but may be improved by optimizing the immune response they induce. This study evaluated immune responses to a trivalent inactivated Porcine Circovirus (PCV) Type 1-Type 2a chimera (cPCV2a), cPCV2b and Mycoplasma hyopneumoniae (MH) (an experimental serial of Fostera® Gold PCV MH, also marketed as Circomax® Myco) vaccine or a bivalent recombinant PCV2a baculovirus expressed ORF2 capsid plus MH vaccine (Circumvent® PCV-M G2).
View Article and Find Full Text PDF